ClinicalTrials.gov
ClinicalTrials.gov Menu

Implant Supported Oral Appliance Treatment of OSA (BIMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03362671
Recruitment Status : Not yet recruiting
First Posted : December 5, 2017
Last Update Posted : March 12, 2018
Sponsor:
Information provided by (Responsible Party):
Benjamin Pliska, University of British Columbia

Brief Summary:

Mandibular advancing oral appliances (OAm) are an effective and increasingly common treatment modality for the management of obstructive sleep apnea (OSA) in adults.

The effectiveness of OAm therapy, however, is dependent on a high level of patient adherence, which may be negatively impacted by treatment side effects - the most significant of which are occlusal changes and tooth movement.

The proposed pilot study will evaluate the efficacy of a novel implant supported OAm in 10 OSA patients who have already been successfully treated with a traditional OAm.

The study will compare OSA specific outcomes with traditional OAm use against novel oral appliance use after one month. This study could potentially validate the novel design features of an effective treatment option for OSA that does not result in tooth movement, which is a significant side effect shared by all existing OAm devices.

Ultimately, this study could lead to increased treatment adherence and better OSA patient health outcomes in the future.


Condition or disease Intervention/treatment Phase
Obstructive Sleep Apnea Device: Implant Supported Mandibular Advancement Oral Appliance Device: Orthodontic Mini Implant Not Applicable

Detailed Description:

Mandibular advancement oral appliances (OAm) are devices that keep the airway open during sleep by pulling the lower jaw forward. OAm have been shown to be an effective treatment for both mild and severe OSA. OSA is a chronic disease and there is no cure. OSA treatments depend on high patient adherence for long term effectiveness.

Currently marketed OAm devices attach to the teeth as a way of holding the jaw in position. However, attaching directly to the teeth causes unwanted tooth movement with long term OAm use. As a result, some long-term users of OAm have stopped treatment due to a decrease in quality of life caused by tooth movement. Accordingly, the changes in tooth position can be seen as a limitation of the existing appliances. For this reason, there is a strong need for a type of treatment that can effectively pull the jaw forward without causing movement of the teeth, which is inevitable with the way the current OAm devices work.

This trial is a pilot study to find out if a novel OAm device is an effective treatment for OSA. The novel OAm device does not contact the teeth directly but instead attaches to orthodontic mini implants (OMIs) in the jaw. 10 OSA patients who have previously been successfully treated with a traditional OAm appliance will be fitted with the novel oral appliance. Participants will be fitted with 6 OMIs following standard practice and the bespoke oral appliance will be manufactured and delivered to the patient for use.

Prior to receiving treatment, participants will undergo a baseline assessment where demographic, anthropometric, and specific periodontal health data will be collected. Daytime sleepiness will be assessed and at-home sleep test will be used to establish baseline sleep parameters with the existing appliance.

Follow up sleep tests will be completed 1 month after initiation of treatment with the new appliance. ESS questionnaires and treatment experience interviews will be completed at 1 month and 4 months after the start of treatment with the new appliance. Treatment adherence and OMI side effects will be monitored throughout the study. Patients will be given the option of continuing treatment with the novel device or having the implants removed and returning to treatment with their previous OAm.

To directly address the primary aim of this study, OSA related parameters will be measured by a combination of methods including at-home sleep tests and Epworth Sleepiness Scale (ESS) questionnaires. Secondary outcome variables to assess treatment adherence and satisfaction include self-reported adherence data using sleep diaries, experience interviews and assessing OMI side effects throughout the study.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bimaxillary Implant Supported Mandibular Advancement Pilot
Estimated Study Start Date : April 2018
Estimated Primary Completion Date : October 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arm Intervention/treatment
Experimental: Treatment Group
Participants will be treated with a novel experimental implant supported mandibular advancement oral appliance, which uniquely attaches to orthodontic mini implants (OMIs) in the jaw. Participants will be fitted with OMIs per standard clinical practice prior to treatment with the novel oral appliance.
Device: Implant Supported Mandibular Advancement Oral Appliance
This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.

Device: Orthodontic Mini Implant
Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
Other Name: Temporary Anchorage Devices (TADs)




Primary Outcome Measures :
  1. Change in Apnea-Hypopnea Index (AHI) [ Time Frame: Data collected at 0, and 1 months after initiation of treatment with the new appliance. ]
    Indication of the severity of sleep apnea. The AHI is calculated by dividing the number of apnea events by the number of hours of sleep. This outcome will assess the change in AHI over time.


Secondary Outcome Measures :
  1. Daytime Sleepiness [ Time Frame: Data collected at 0, 1, and 4 months after initiation of treatment with the new appliance. ]
    Evaluation of OSA specific fatigue using Epworth Sleepiness Scale (ESS) questionnaire. ESS measures daytime sleepiness via 8 questions that ask about daytime sleepiness during common everyday conditions. The potential range of scores for any questions is from 0 to 3. Higher values represent worse outcomes. Their are no subscales for ESS. The answers to the questions are all summed up. Total score ranges between 0 and 24. A score above 10 indicates daytime sleepiness with higher scores indicating more sleepiness.

  2. Arterial Oxygen Saturation [ Time Frame: Data collected at 0, 1, and 4 months after initiation of treatment with the new appliance. ]
    Using a pulse oximeter to determine the percentage of hemoglobin binding sites in the bloodstream occupied by oxygen.

  3. Treatment Adherence [ Time Frame: Data will be collected by the research team 4 months after initiation of treatment with the new appliance. ]
    Self-reported use of the appliance by recording the number of hours per night and the number of nights per week that the appliance is used.

  4. Patient Experience [ Time Frame: Data collected 1 and 4 months after initiation of treatment with the new appliance. ]
    Subjective patient experience data collected from semi-structured interviews.

  5. Mini Implant Side Effects - Mobility [ Time Frame: Data collected at 1 week, 1 month and 4 months after initiation of treatment with the new appliance. ]
    Using tactile assessment to determine implant mobility per Ngiam et al. Mobility will be graded from 0-2 depending on severity. 0 represents no mobility whereas 2 represents mobility greater than 1mm. There is an additional option for total mobility or implant loss.

  6. Mini Implant Side Effects - Gingival Irritation [ Time Frame: Data collected at 1 week, 1 month and 4 months after initiation of treatment with the new appliance. ]
    Gingival irritation will be determined using tactile/visual assessment. Irritation will be scored as either YES (present) or NO (absent).

  7. Mini Implant Side Effects - Soreness [ Time Frame: Data collected at 1 week, 1 month and 4 months after initiation of treatment with the new appliance. ]
    Soreness will be determined using tactile/visual assessment and self-reported by patients. Soreness will be scored as either YES (present) or NO (absent).

  8. Mini Implant Side Effects - Jaw Pain [ Time Frame: Data collected at 1 week, 1 month and 4 months after initiation of treatment with the new appliance. ]
    Jaw pain will be determined using tactile/visual assessment and self-reported by patients. Jaw pain will be scored as either YES (present) or NO (absent).

  9. Mini Implant Side Effects - Excess Salivation [ Time Frame: Data collected at 1 week, 1 month and 4 months after initiation of treatment with the new appliance. ]
    Excess salivation will be determined using visual assessment and self-reported by patients. Excess salivation will be scored as either YES (present) or NO (absent).

  10. Mini Implant Side Effects - Other [ Time Frame: Data collected at 1 week, 1 month and 4 months after initiation of treatment with the new appliance. ]
    A brief description of any other side effects will be self-reported by patients.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

This trial will recruit 10 patients with an objective diagnosis of obstructive sleep apnea who are not naïve to treatment. The inclusion criteria are:

  • Currently receive or have previously received successful OSA treatment with an OAm;
  • Age 25 - 65 years old, who are able to freely provide informed consent;
  • Body Mass Index (BMI) ≤ 35;
  • Apnea-Hypopnea Index (AHI) within the range 5≤AHI≤50 documented with polysomnography in the last 2 years ***OR***
  • Respiratory Disturbance Index (RDI) within the range 20 ≤ RDI ≤ 50 documented with Level III portable sleep test ***OR***
  • Oxygen Desaturation Index (ODI) ≥ 10

Exclusion Criteria:

The patient is excluded if it meets any of the following criteria:

  • Extensive periodontal disease;
  • Bleeding disorder;
  • Bone metabolic disorder
  • Immunocompromised
  • Diabetes mellitus
  • Xerostomia
  • Titanium allergy
  • Insufficient vertical opening to accommodate treatment with OAm;
  • Pregnancy (if a participant becomes pregnant during the trial, the participant will be withdrawn from the study).
  • Uncontrolled congestive heart failure (defined as a prior clinical diagnosis, an ejection cut-off of 40% or clinical sign in the opinion of a primary care physician or cardiologist) that makes it unsafe in the opinion of the investigators for the subject to participate in the trial;
  • Coronary artery disease unless stable for at least 6 months and considered by the investigators to have a stable disease;
  • Any history of angina, myocardial infarction or stroke;
  • Any history of major depressive disorder along with current moderate-severe disease;
  • Active cancer management (unless in remission for more than 1 year);
  • Known renal failure (with need for dialysis)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03362671


Contacts
Contact: Benjamin T Pliska, DDS 604-822-7237 pliska@dentistry.ubc.ca

Locations
Canada, British Columbia
University of British Columbia Not yet recruiting
Vancouver, British Columbia, Canada, V6T 1Z3
Contact: Benjamin T Pliska, DDS    604-822-7237    pliska@dentistry.ubc.ca   
Contact: Eleanor F Cawthorne, BSc    604-827-0690    ecawthorne@dentistry.ubc.ca   
Principal Investigator: Benjamin T Pliska, DDS         
Sponsors and Collaborators
University of British Columbia
Investigators
Principal Investigator: Benjamin T Pliska, DDS University British Columbia

Responsible Party: Benjamin Pliska, Assistant Professor, University of British Columbia
ClinicalTrials.gov Identifier: NCT03362671     History of Changes
Other Study ID Numbers: 14G31862
First Posted: December 5, 2017    Key Record Dates
Last Update Posted: March 12, 2018
Last Verified: March 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Benjamin Pliska, University of British Columbia:
OSA
Mandibular Advancement Splint
Oral Appliance
Treatment
Orthodontic Implants

Additional relevant MeSH terms:
Sleep Apnea, Obstructive
Sleep Apnea Syndromes
Apnea
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases